Hormonal
Activation of the CML-RAGE axis in adipose tissue drives obesity-associated inflammation and insulin resistance by dysregulating adipokine expression (increasing pro-inflammatory cytokines and decreasing adiponectin).
This research suggests that obesity-related insulin resistance is driven by a specific molecular loop involving CML and RAGE in fat tissue. While this paper does not prescribe a direct intervention, it implies that reducing the formation of CML (an advanced glycation end product formed via lipid peroxidation) or blocking RAGE could theoretically improve insulin sensitivity. For now, strategies that reduce oxidative stress and lipid peroxidation (often associated with high sugar/fat diets) may indirectly mitigate this pathway.
activation of the CML–RAGE axis plays an important role in obesity-associated inflammation and insulin resistance... CML induced a dysregulation of inflammatory adipokines in adipocytes via a RAGE-dependent pathway.
Why this rating
Strong evidence from human tissue, in vitro models, and genetically modified mouse models (RAGE-/-).
Source
N <sup>ε</sup> -(Carboxymethyl)lysine-Receptor for Advanced Glycation End Product Axis Is a Key Modulator of Obesity-Induced Dysregulation of Adipokine Expression and Insulin Resistance
Katrien H.J. Gaens et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2014
DOI 10.1161/atvbaha.113.302281
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →